Nektar Therapeutics
NASDAQ:NKTR
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Nektar Therapeutics
NASDAQ:NKTR
|
2B USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
866.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
572.1B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
243.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
219.1B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
225.5B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
282.6B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
240.1B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
155.9B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Nektar Therapeutics
Glance View
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. The company is headquartered in San Francisco, California and currently employs 740 full-time employees. The firm's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Nektar Therapeutics is 100%, which is above its 3-year median of 72.7%.
Over the last 3 years, Nektar Therapeutics’s Gross Margin has increased from 76.4% to 100%. During this period, it reached a low of 59.2% on Jun 30, 2024 and a high of 100% on Jan 1, 2026.
